Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - F-star Therapeutics, Inc. | sbph-ex321_492.htm |
| EX-31.2 - EX-31.2 - F-star Therapeutics, Inc. | sbph-ex312_491.htm |
| EX-31.1 - EX-31.1 - F-star Therapeutics, Inc. | sbph-ex311_490.htm |
| EX-21.1 - EX-21.1 - F-star Therapeutics, Inc. | sbph-ex211_488.htm |
| EX-10.18 - EX-10.18 - F-star Therapeutics, Inc. | sbph-ex1018_487.htm |
| 10-K - 10-K - F-star Therapeutics, Inc. | sbph-10k_20161231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement on Form S-8 (333-212047) of our report dated February 14, 2017 relating to the consolidated financial statements of Spring Bank Pharmaceuticals, Inc. and its subsidiaries appearing in this Annual Report on Form 10-K of Spring Bank Pharmaceuticals, Inc. and its subsidiaries for the year ended December 31, 2016.
/s/ RSM US LLP
Boston, Massachusetts
February 14, 2017